

TAL-1/SCL and Its Partners E47 and LMO2 Up-Regulate VE-Cadherin Expression in Endothelial Cells^{∇†}

Virginie Deleuze,^{1,2¶} Elias Chalhoub,^{1,2§} Rawan El-Hajj,^{1,2} Christiane Dohet,^{1,2} Mikaël Le Clech,^{1,2‡} Pierre-Olivier Couraud,^{3,4} Philippe Huber,⁵ and Danièle Mathieu^{1,2*}

Institut de Génétique Moléculaire de Montpellier CNRS, UMR5535, Montpellier, France¹; Université de Montpellier 2, Montpellier, France²; Institut Cochin, INSERM/CNRS, Paris, France³; Université Paris 5, Paris, France⁴; and CEA, INSERM, Grenoble, France⁵

Received 21 March 2006/Returned for modification 20 May 2006/Accepted 2 January 2007

The basic helix-loop-helix TAL-1/SCL essential for hematopoietic development is also required during vascular development for embryonic angiogenesis. We reported that TAL-1 acts positively on postnatal angiogenesis by stimulating endothelial morphogenesis. Here, we investigated the functional consequences of TAL-1 silencing in human primary endothelial cells. We found that TAL-1 knockdown caused the inhibition of in vitro tubulomorphogenesis, which was associated with a dramatic reduction in vascular endothelial cadherin (VE-cadherin) at intercellular junctions. Consistently, silencing of TAL-1 as well as of its cofactors E47 and LMO2 down-regulated *VE-cadherin* at both the mRNA and the protein level. Endogenous *VE-cadherin* transcription could be activated in nonendothelial HEK-293 cells by the sole concomitant ectopic expression of TAL-1, E47, and LMO2. Transient transfections in human primary endothelial cells derived from umbilical vein (HUVECs) demonstrated that *VE-cadherin* promoter activity was dependent on the integrity of a specialized E-box associated with a GATA motif and was maximal with the coexpression of the different components of the TAL-1 complex. Finally, chromatin immunoprecipitation assays showed that TAL-1 and its cofactors occupied the *VE-cadherin* promoter in HUVECs. Together, these data identify *VE-cadherin* as a bona fide target gene of the TAL-1 complex in the endothelial lineage, providing a first clue to TAL-1 function in angiogenesis.

During development, hematopoietic precursors and endothelial cells (ECs) arise in close association from a common precursor, the hemangioblast. Although the hemangioblast per se has not yet been identified in vivo, coexpression of blood and endothelial genes, as well as the dependence of both lineages on some of these shared genes, supports its existence. One such gene is *TAL-1/SCL*, hereafter referred to as *TAL-1* (reviewed in reference 25). *TAL-1*, initially identified at the sites of chromosomal rearrangements in human acute T-cell leukemia, encodes a transcription factor from the basic-helix-loop-helix family. Gene knockout studies with mice have revealed the essential role of *tal-1* in the establishment of the hematopoietic system (33, 37, 38, 41) and its specific requirement for erythroid and megakaryocytic lineage formation (15, 28).

To exert its hematopoietic functions, TAL-1 protein acts through both DNA-binding-dependent and -independent mechanisms (32, 36). TAL-1 forms heterodimers with the E basic-helix-loop-helix proteins E47 and HEB and binds to a specific E-box (16). TAL-1 can either activate or repress transcription, depending on its association with other essential

hematopoietic transcription factors, such as GATA-1 or GATA-2 and LMO2 (5, 21, 44–46). TAL-1 also interacts with coactivators (p300 and p/CAF) and corepressors (mSin3A and ETO-2), the function of which is linked to histone acetyltransferases or deacetylases (12, 17, 18, 40).

Loss- and gain-of-function studies with different vertebrate models showed that *TAL-1* is also involved in the formation of the vascular system (10, 11, 31, 32, 43). *Tal-1*^{-/-} embryos, rescued for *Tal-1* expression in primitive hematopoietic cells, exhibit defective yolk sac angiogenesis, due to an intrinsic defect in *Tal-1*^{-/-} endothelial cells (43). In adults, TAL-1 expression is undetectable in quiescent endothelium but is present in newly formed blood vessels (20, 35), including tumor vasculature (4). Together, these observations associate *TAL-1* activity with both developmental and adult angiogenesis. We previously reported that TAL-1 acts as a positive factor for postnatal angiogenesis by modulating the migration properties of ECs and activating the morphogenetic events that lead to tubular structures. Importantly, the expression of a dominant negative mutant of TAL-1 in ECs completely abolished in vitro morphogenesis, as well as in vivo angiogenesis (23).

To understand how TAL-1 modulates angiogenesis, we investigated the functional effects of TAL-1 silencing, mediated by RNA interference, in human primary ECs. We show here that TAL-1 knockdown completely impairs in vitro tubulogenesis by down-regulating vascular endothelial cadherin (VE-cadherin) expression at both the protein and the mRNA level. Moreover, we provide evidence that TAL-1, in association with its partners E47, LMO2, GATA-2, and Ldb1, up-regulates *VE-cadherin* gene expression through direct binding to the *VE-cadherin* promoter.

* Corresponding author. Mailing address: Institut de Génétique Moléculaire de Montpellier CNRS, UMR5535, Montpellier, France. Phone: 33 467 613 655. Fax: 33 467 040 231. E-mail: danièle.mathieu@igmm.cnrs.fr.

§ Present address: University of Beirut, Beirut, Lebanon.

‡ Present address: Max Planck Institute for Biochemistry, 82152 Martinsried, Germany.

¶ V. Deleuze and E. Chalhoub contributed equally to the work.

† Supplemental material for this article may be found at <http://mc.manuscriptcentral.com/mcb>.

∇ Published ahead of print on 22 January 2007.

MATERIALS AND METHODS

Cell cultures. Human primary endothelial cells derived from umbilical vein (HUVECs) were obtained from Cambrex (France), and ECs from human cord blood (UCB-ECs) were prepared and cultured as described previously (23). HEK-293 cells were grown in Dulbecco's modified Eagle's medium with 10% fetal calf serum.

Reagents and antibodies. Human epidermal growth factor, human-basic fibroblast growth factor (bFGF), and human vascular endothelial growth factor (VEGF) were purchased from Peprotech (France), and Matrigel and rat type I collagen were purchased from BD Biosciences (France). The following antibodies were used in this study: 3BTL73 and 2TL136, two mouse monoclonal antibodies (MAb) directed against human TAL-1 (35); MAb anti- β -actin (clone AC-15; Sigma); MAb anti- β -catenin (clone 14; Transduction Laboratories); MAb anti-E47 (clone G127-32) and MAb anti-CD31/PECAM (clone WM-59 BD) from Pharmingen; MAb anti-VE-cadherin (clone BV9 [22] and clone 75; Transduction Laboratories); MAb anti-N-cadherin (clone 32; BD Biosciences); polyclonal rabbit anti-general transcription factor IIB (TFIIB) (sc-225; Santa Cruz Biotechnology, Inc.); and polyclonal goat anti-human LMO2 (AF2726; R&D Systems).

siRNA transfections. Small interfering RNA (siRNA) transfections in ECs were carried out using Magnetofection technology (polyMag; OZ Biosciences, France). Two successive transfections were performed 24 h apart, with a 30 nM siRNA concentration. For E47 and LMO2 silencing, a mixture of two RNA duplexes was used. The sequences of duplex RNAs are presented in the supplemental material.

Proliferation assays. HUVECs or UCB-ECs (4×10^4) were seeded in collagen-coated 24-well plates and transfected with siRNAs as described above. After 3 days in culture, the number of viable cells per well was estimated by an MTT (3-[4,5-dimethylthiazol-2-yl]-diphenyltetrazolium bromide) assay (Sigma), following the manufacturer's instructions.

In vitro three-dimensional (3D) tubulogenesis in collagen I gels. HUVECs (8×10^4) in basal medium (MCDDB131 with 1% fetal calf serum, $1 \times$ insulin transferrin supplement, 2 mM glutamine, and 25 mM NaHCO_3) were mixed with neutralized collagen I cold solution in wells of a 24-well plate to get a 0.9-mg/ml collagen concentration. Capillary tube formation was stimulated by the addition of basal medium supplemented with phorbol myristate acetate (80 nM), VEGF, and bFGF (20 ng/ml). Photographs were taken on a Zeiss Axiovert 25 inverted-phase microscope coupled to a digital Canon power shot camera. The digitalized images were mounted using Adobe Photoshop and Adobe Illustrator.

In vitro two-dimensional (2D) angiogenesis on Matrigel. HUVECs (8×10^4) in complete EC medium were added to wells of a 24-well plate coated with Matrigel (BD Biosciences) and incubated at 37°C for 24 h. When required, cells were recovered from Matrigel as described previously (23), and total RNAs were prepared with an RNeasy kit (QIAGEN).

Immunofluorescence analyses. Twenty-four hours after siRNA transfections, HUVECs were trypsinized and seeded onto gelatin-coated coverslips for 24 h. Primary MABs were revealed with fluorescein isothiocyanate-conjugated goat anti-mouse immunoglobulins G (IgGs) (Sigma). Cell nuclei were counterstained with Hoechst bisbenzidine (Sigma). Single-plane images were captured using a MicroMax 1300 charge-coupled-device camera (Princeton Instruments, Trenton, NJ) driven by Metamorph (Universal Imaging, Westchester, PA). The images were imported as TIFF files that were mounted using Adobe Photoshop and Adobe Illustrator.

RT-qPCR. Reverse transcription was carried out as described previously (23). PCR amplification reactions were performed using a light cycler (Roche). The primer sequences used for real-time quantitative PCR (RT-qPCR) are indicated in the supplemental material.

Transient transfections. The reporter constructs containing fragments of the human *VE-cadherin* promoter region upstream of the firefly luciferase gene have been described previously (34). Mutations of the E-boxes -101 and -784 and GATA -798 in the promoter were performed using a QuikChange II site-directed mutagenesis kit (Stratagene). Oligonucleotides used for these mutations are indicated in the supplemental material. Plasmid DNAs were transfected with Lipofectamine Plus (Life Technology) in HUVECs or precipitated with calcium phosphate in HEK-293 cells. The TK-RL plasmid encoding *Renilla* luciferase was cotransfected with firefly luciferase reporters to correct for transfection efficiency. Normalized firefly luciferase activities were determined using a dual luciferase kit (Promega). Human *TAL-1* (wild type and Δ -bas [mutant that lacks a DNA-binding domain]) and *E47* cDNAs were subcloned into pRc/CMV. The expression vector encoding hemagglutinin-tagged LMO-2 was provided by O. Bernard (Paris, France). The cDNAs encoding Ldb1 and GATA-2, provided by T. Hoang (Montreal, Quebec, Canada), were subcloned into pcDNA-3. The

cDNAs encoding *TAL-1* mutants SCL-FL and SCL-F-G (39), provided by C. Porcher (Oxford, United Kingdom), were subcloned in pcDNA-3.

ChIP assays. Chromatin immunoprecipitation (ChIP) assays were performed using exponentially growing HUVECs and are described in detail in the supplemental material. Cleared chromatin corresponding to 1×10^7 to 1.5×10^7 cells was incubated with antibodies against *TAL-1*, *E47/E2A*, *GATA-2*, *LMO-2*, and control IgGs. Aliquots of immunoprecipitated DNAs were analyzed in triplicate by real-time quantitative PCR with the indicated primers. The genomic region downstream of the *VE-cadherin* gene (+40932) was amplified as a negative control. Enrichment (*n*-fold) of target genomic regions immunoprecipitated by each specific antibody was normalized to the levels obtained with species-matched control IgGs and plotted as the increase over the level of enrichment at the negative-control region.

Statistical analysis. All results are expressed as means \pm standard deviations (SD). Significance of differences was determined with the Student *t* test, with significance at *P* of <0.05.

RESULTS

***TAL-1* knockdown disrupts endothelial morphogenesis without affecting cell survival.** siRNA was used to reduce the levels of endogenous *TAL-1* protein in HUVECs or UCB-ECs. An *eGFP* (gene encoding enhanced green fluorescent protein) siRNA, the sequence of which matches no known human gene, was used as a control. *TAL-1* siRNA treatment suppressed the expression of *TAL-1* protein to a level that was undetectable by immunoblotting (Fig. 1A, left). Both HUVECs and UCB-ECs carrying either *TAL-1* siRNA or control siRNA grew at similar rates (Fig. 1A, right), indicating that *TAL-1* is not essential for in vitro survival and growth of ECs. Moreover, *TAL-1*-silenced HUVECs seeded 48 h posttransfection onto coated glass coverslips formed a confluent cell monolayer similarly to control cells (Fig. 1B).

We assessed the effects of *TAL-1* knockdown on endothelial morphogenesis tested in 2D Matrigel cultures or in 3D collagen I gels. When seeded on 2D Matrigel, HUVECs treated with *eGFP* siRNA rapidly underwent morphogenesis, and by 24 h, virtually all cells had formed continuous cords with branching sprouts and anastomosis (Fig. 1C, left). *TAL-1* siRNA-treated HUVECs also organized a network by 24 h. However, higher magnification revealed that the *TAL-1*-silenced ECs were still assembled into chains, albeit with poor cell-cell contacts, and did not undergo morphogenetic changes. When seeded within a 3D collagen gel with VEGF, bFGF, and phorbol myristate acetate, ECs align with each other, become polarized, and form tubular structures (6). Control ECs had formed an interconnected network of tubules 48 h after seeding (Fig. 1C, right). In contrast, *TAL-1*-silenced HUVECs did not form tubular structures, and similarly to the 2D culture, remained dispersed, nonpolarized, and without any cell-cell contact. These results indicate that the lack of *TAL-1* does not affect EC survival or migration but impairs in vitro morphogenesis.

***TAL-1* or *E47* knockdown impairs junctional *VE-cadherin* distribution.** To assemble into tubular structures, ECs must establish contacts with their neighbors and with the extracellular matrix. Cell-cell adhesion is initiated and maintained by adherens junctions. The abnormal intercellular contacts observed in both 2D and 3D networks formed with ECs lacking *TAL-1* (Fig. 1C) strongly suggested that *TAL-1* knockdown might directly affect adherens junction formation. *VE-cadherin* is the adhesion component of endothelial adherens junctions and is directly involved in the formation and maintenance of cell-cell contacts (7). ECs also express platelet endothelial




FIG. 1. *TAL-1* knockdown impairs in vitro morphogenesis. (A and B) *TAL-1* silencing does not affect EC survival or growth. HUVECs or UCB-ECs transfected with *TAL-1* or control siRNA (*eGFP*) were tested for their proliferative properties. (A) (Left) *TAL-1* expression was assessed in whole-cell lysates (30 μ g) by immunoblotting with the anti-*TAL-1* MAb. The blot was reprobbed with an anti-TFIIB antibody to control protein loading. (Right) Cells were transfected with the indicated siRNAs. MTT assays were carried out 48 h after the second transfection. Each bar is the mean \pm SD of cell numbers relative to numbers of control siRNA-treated cells from three independent experiments performed in sextuplicate. NT, not transfected. (B) Forty-eight hours posttransfection, the same numbers of cells were seeded onto gelatin-coated coverslips. Shown are phase-contrast microscopic photographs after 24 h of culture, taken using a 10 \times objective. The experiments were repeated at least three times with similar results. (C) *TAL-1* knockdown affects in vitro angiogenesis. HUVECs were transfected with *TAL-1* or control *eGFP* siRNA and analyzed 24 h after the second transfection for their ability to produce in vitro capillary-like structures in 2D Matrigel culture or a tubular network in 3D collagen I gel. Shown are phase-contrast microscopic photographs, taken using a 10 \times objective, after 24 h of culture on Matrigel (left) or after 48 h in collagen I gel (right). The experiments were repeated at least three times with similar results.

cell adhesion molecule (PECAM), which promotes homophilic adhesion between ECs. Previous studies have shown that antibodies blocking VE-cadherin or PECAM interactions impair HUVEC tubulogenesis in collagen I gels (48). These observations prompted us to assess whether *TAL-1* knockdown alters VE-cadherin or PECAM expression at the cell surface. Strong VE-cadherin staining was observed at cell-cell contacts in control ECs (Fig. 2). In striking contrast, VE-cadherin staining was no longer present at sites of cell-cell contacts in *TAL-1*-silenced ECs. Conversely, both control and *TAL-1*-silenced ECs displayed similar results of PECAM and β -catenin staining at cell-cell contacts. β -Catenin recruitment at the intercellular region in the absence of VE-cadherin suggested that N-cadherin might have replaced VE-cadherin at cell-cell junctions in *TAL-1*-silenced ECs (29). Indeed, while control cells exhibited

only a diffuse distribution of N-cadherin over the cell surface, *TAL-1*-silenced ECs displayed some N-cadherin clustering at cell-cell junctions in addition to nonjunctional distribution. These data indicated that *TAL-1* silencing either disrupted VE-cadherin localization at intercellular junctions or decreased VE-cadherin content in ECs.

Dimerization of *TAL-1* with E proteins is a prerequisite for all of its functions. Since E47 is the major dimerization partner of *TAL-1* in ECs (23), we investigated whether E47 silencing might also influence VE-cadherin expression. E47-specific siRNAs dramatically decreased E47 protein expression (Fig. 3A, right) and produced the same effects as *TAL-1* siRNA, i.e., a strong reduction of VE-cadherin staining at the cell-cell junctions (Fig. 2). Consistently, E47 knockdown also impaired in vitro tubulogenesis of HUVECs (see Fig. S1 in the supplemental material).




FIG. 2. *TAL-1* or *E47* knockdown disrupts junctional VE-cadherin distribution. HUVECs were transfected with the indicated siRNA and, 24 h posttransfection, were trypsinized and seeded onto coverslips overnight. Cells were stained for VE-cadherin, PECAM-1, β -catenin, and N-cadherin, and the nuclei were counterstained. Micrographs were taken using a 40 \times objective. The pictures are representative of at least three independent experiments. Bar, 20 μ M.

We used immunoblotting to determine whether the absence of VE-cadherin at cell-cell junctions induced by *TAL-1* or *E47* knockdown was associated with variations in the amount of intracellular VE-cadherin. Indeed, *TAL-1*-silenced HUVECs showed significant decreases in VE-cadherin protein levels, namely, 52%, 60%, and 74% by 24, 48, and 72 h posttransfection, respectively, relative to results with control cells (Fig. 3A, left). Similarly, *E47* silencing resulted in a 47% decrease in intracellular VE-cadherin protein levels by 48 h posttransfection (Fig. 3A, right). Thus, silencing of either *TAL-1* or *E47* reduces VE-cadherin expression.

In light of this, using RT-qPCR, we assessed whether this reflected decreased mRNA levels. *VE-cadherin* mRNA levels were significantly reduced in *TAL-1*-silenced ECs, namely, by 49%, 54%, and 63% at 24, 48, and 72 h posttransfection, respectively (Fig. 3B, left), compared to results with control cells. Similarly, *E47* silencing induced a strong reduction over 70% of *VE-cadherin* mRNA levels (Fig. 3B, right).

Collectively, these data show that silencing of either *TAL-1* or *E47* disrupts endothelial intercellular junctions by down-regulating *VE-cadherin* expression at both the mRNA and the protein level.

LMO2 silencing down-regulates VE-cadherin expression. In hematopoietic cells, the *TAL-1*/*E* heterodimers regulate gene expression through association with the LIM-only protein *LMO2* (25). Given its key role in the endothelial lineage (47), we wondered if *LMO2* also influences *VE-cadherin* expression. We reported that *TAL-1* expression is modulated during the process of in vitro angiogenesis (23). We performed a time course analysis of *VE-cadherin* and *LMO2* mRNA expression

during in vitro angiogenesis on 2D Matrigel (Fig. 4A). Remarkably, both *VE-cadherin* and *LMO2* mRNA levels paralleled those of *TAL-1*; they showed a strong decrease when cells were migrating to form the cell cord network, i.e., within the first 6 h, followed by an up-regulation during the morphogenetic events, i.e., the 12- to 24-h time points. These data strongly supported the possibility that *LMO2* might also modulate *VE-cadherin* expression.

We assessed the effects of *LMO2* silencing on *VE-cadherin* expression. *LMO2* siRNA treatment efficiently suppressed *LMO2* mRNA expression in HUVECs (Fig. 4B, top). *LMO2* knockdown was associated with a 60% reduction in VE-cadherin expression at both the protein (Fig. 4B, middle) and the mRNA (Fig. 4B, bottom) level. Similarly to *TAL-1*- and *E47*-silenced HUVECs, *LMO2*-silenced cells failed to display VE-cadherin staining at the cell-cell junctions (not shown) and to generate tubules in 3D collagen gels (see Fig. S1 in the supplemental material).

Coexpression of *TAL-1*, *E47*, and *LMO2* up-regulates the *VE-cadherin* gene in nonendothelial cells. We investigated whether *TAL-1*, *E47*, and *LMO2* could also influence endogenous *VE-cadherin* expression in a nonendothelial cell environment. We chose human embryonic kidney 293 cells (HEK-293) since they express neither *TAL-1* nor *LMO2* and they display low constitutive amounts of *VE-cadherin* mRNAs as detected by RT-qPCR. Basal transcription of *VE-cadherin* was insensitive to exogenous *TAL-1* or *E47*, either alone or together, and to *LMO2* alone (Fig. 4C). In contrast, coexpression of *TAL-1* and *E47* with *LMO2* caused a sixfold increase in *VE-cadherin* mRNA levels. We tested the effects of several *TAL-1* mutants




FIG. 3. VE-cadherin expression is down-regulated in *TAL-1*- or *E47*-silenced ECs. HUVECs were transfected with the indicated siRNA. Whole-cell extracts and total RNAs were prepared at the indicated time points after transfection and monitored for VE-cadherin (VE-CAD) expression. (A) TAL-1, E47, and intracellular VE-cadherin protein expression levels were analyzed by immunoblotting. β -Actin or TFIIB expression was monitored for normalization of protein loading. Protein content from control siRNA-treated cells was arbitrarily set at 1. The images (top) are representative of three independent experiments, and the means \pm SD of the indicated protein relative to that of β -actin are shown (bottom). (B) *VE-cadherin* mRNA levels were analyzed by RT-qPCR. The signals of *VE-cadherin* mRNA were normalized to that of *GAPDH* (gene encoding glyceraldehyde-3-phosphate dehydrogenase). Data shown are the means \pm SD from three independent experiments. The *VE-cadherin* mRNA content from control siRNA-treated cells was arbitrarily set at 1.

in this activation: Δ bas, which lacks a DNA-binding domain; TAL-1-FL, which is unable to form a heterodimer with E proteins (39); and TAL-1-FG, which fails to interact with LMO2 (39). The coexpression of each individual TAL-1 mutant with E47 and LMO2 failed to stimulate *VE-cadherin* expression. Thus, the binding of TAL-1 to DNA and its interac-

tion with E47 as well as with LMO2 are required for *VE-cadherin* transcriptional activation in HEK-293 cells.

TAL-1, E47, and LMO2 regulate the *VE cadherin* promoter in HUVECs. Our above-described results suggested that TAL-1, E47, and LMO2 regulate *VE-cadherin* expression at the transcriptional level. To test this possibility, we transfected




FIG. 4. LMO-2 activity correlates with *VE-cadherin* up-regulation. (A) Time course analysis of *TAL-1*, *VE-cadherin*, and *LMO-2* mRNA expression during in vitro angiogenesis. HUVECs were plated on Matrigel and cultured for 24 h. Cells were recovered at the indicated time points to prepare total RNA. Gene expression was analyzed by RT-qPCR. The signals of *TAL-1*, *VE-cadherin*, and *LMO-2* mRNAs were normalized to that of *GAPDH* (gene encoding glyceraldehyde-3-phosphate dehydrogenase). Data shown are mRNA levels relative to the corresponding mRNA levels of exponentially growing cells, which were assigned a value of 1. Results from two independent experiments (Exp. 1 and Exp. 2) are shown. (B) *LMO-2* silencing down-regulates *VE-cadherin* expression. HUVECs were transfected with control or *LMO-2* siRNA. Forty-eight hours posttransfection, *VE-cadherin* protein expression was analyzed by immunoblotting; β -actin expression was used to normalize protein loading. The image (middle) is representative of at least three independent experiments. Data shown are *VE-cadherin* protein contents relative to that of control siRNA-treated cells, which was assigned a value of 1 (bottom). *LMO-2* silencing (top) and *VE-cadherin* mRNA expression were monitored by RT-qPCR, and mRNA signals were normalized to that of *GAPDH*. Data shown are mRNA contents relative to that of control siRNA-treated cells, which was assigned a value of 1 (**, $P < 0.01$; ***, $P < 0.001$). (C) Ectopic coexpression of *TAL-1*, *E47*, and *LMO-2* up-regulates *VE-cadherin* expression in nonendothelial cells. HEK-293 cells were cotransfected with the indicated expression vectors. The total amount of DNA (6.5 μ g) was maintained constant with the addition of the corresponding empty vectors. eGFP vector (0.5 μ g) was added to each point to control transfection efficiency. Total RNAs and whole-cell extracts were prepared 48 h posttransfection, and *VE-cadherin* expression was analyzed by RT-qPCR. The expression of ectopic proteins in whole-cell extracts (30 μ g) was monitored by immunoblotting. A representative experiment is shown. *VE-cadherin* mRNA signals were normalized to those of *GAPDH*. Data shown are *VE-cadherin* mRNA contents relative to that of cells transfected with empty vectors, which was assigned a value of 1. Data are the means \pm SD from at least three independent experiments (***, $P < 0.001$).

various human *VE-cadherin* promoter reporter constructs in HUVECs. As described previously (34), all of these constructs were active, where the highest efficiency was observed with the longest promoter fragment, $-3500/-5$ (Fig. 5A). *TAL-1* knock-down caused a significant decrease in the activity of all of the promoter fragments, compared with eGFP siRNA treatment (Fig. 5A, left), but did not affect the heterologous simian virus 40 (SV40) promoter (Fig. 5A, right).

Comparative-genomics sequence analysis is a powerful technique for identifying important regulatory elements in genomic DNA. We aligned the upstream sequences of the *VE-cadherin* gene from several species (human, mouse, rabbit, rat, dog, and elephant) by using the UCSC genome bioinformatics site and found several highly conserved blocks. We searched for potential *cis*-acting binding sites in the human *VE-cadherin* promoter by using the Transcription Element Search System (TESS) and examined the alignment to verify whether these were conserved in all species tested. This study highlighted two highly conserved regions of interest within the *VE-cadherin* promoter ($-150/-80$ and $-800/-770$ [Fig. 5A]), which both contain an E-box consensus in close vicinity of a potential GATA-binding site. This particular E-box-GATA motif arrangement is present in the promoter of several hematopoietic genes found to be

directly regulated by *TAL-1*-containing complexes (1, 5, 21, 27, 44–46).

For the next studies, we used the $-1135/-5$ reporter construct since it contains these two E-box-GATA motif elements. Significantly, *E47* or *LMO2* siRNA treatment also reduced the activity of the *VE-cadherin* promoter by 45% and 55%, respectively (Fig. 5B, left), but not the activity of the SV40 promoter (Fig. 5B, right). Thus, the *VE-cadherin* reporter transfection studies mirrored the effects of *TAL-1*, *E47*, or *LMO2* silencing on endogenous *VE-cadherin* in HUVECs.

Given the presence of these two E-box-GATA motifs in the *VE-cadherin* promoter, we tested whether ectopic expression of the different components of the *TAL-1* complex as described for hematopoietic cells may influence the *VE-cadherin* promoter. Transient transfections were carried out in HUVECs using the $-1135/-5$ construct (Fig. 5C). The expression of *TAL-1*, *E47*, *GATA-2*, or *Ldb1* induced a significant increase in promoter activity, i.e., 1.7-, 2.6-, 2.2-, or 1.6-fold, respectively. However, maximal activation (fivefold) was observed with the coexpression of the five components, including *LMO2*. These results showed that *TAL-1* in association with *E47*, *LMO2*, *GATA-2*, and *Ldb1* activates the *VE-cadherin* promoter in endothelial cells.




FIG. 5. Silencing of TAL-1, E47, or LMO2 reduces *VE-cadherin* promoter activity. (A) (Top) HUVECs were transfected by control or TAL-1 siRNA and 24 h later with the indicated reporter containing fragments derived from the human *VE-cadherin* promoter, for which the negative number indicates the position of the first nucleotide of the gene segment relative to the transcription start site (+1), or with the pGL3 promoter reporter (SV40). Luciferase activity was assayed as described previously (24). Relative luciferase activities are presented as increases (n -fold) over the activity of the minimal promoter (the $-166/-5$ construct) treated with control *eGFP* siRNA, which was assigned a value of 1. Each bar is the mean \pm SD from at least three independent experiments, each performed in triplicate. TAL-1 silencing was monitored by immunoblot analysis (not shown). (Bottom) The *VE-cadherin* promoter contains two conserved E-box-GATA motifs. Nucleotide sequences of the two highly conserved regions from the human *VE-cadherin* promoter are shown. The E-boxes E^{-784} and E^{-101} are indicated by dark-gray boxes and GATA-binding sites G^{-798} and G^{-128} by light-gray boxes. The ETS-binding sites (EBS) from the minimum promoter (34) are underlined. (B) HUVECs were transfected with the indicated siRNAs and either with the $-1135/-5$ reporter construct (left) or with the pGL3 promoter (right). E47 silencing was monitored by immunoblot analysis and LMO2 silencing by RT-qPCR (not shown). Data are the means \pm SD from at least three independent experiments, each performed in triplicate, and are shown relative to the luciferase activity of cells transfected with control siRNA. (C) HUVECs were cotransfected with the $-1135/-5$ reporter construct and the indicated expression vectors. The total amount of DNA was maintained constant with the addition of the corresponding empty vectors. Data are the means \pm SD from at least three independent experiments, each performed in triplicate, and are shown relative to the luciferase activity of cells transfected with empty vector, which was arbitrarily set at 1 (**, $P < 0.01$; ***, $P < 0.001$). Ectopic expression was monitored by Western blot analysis or RT-qPCR (see Fig. S2 in the supplemental material).

***VE-cadherin* promoter activity depends on a specialized E-box-GATA element.** To assess the significance of the E-box motifs identified by sequence comparison analysis (E^{-101} and E^{-784} [Fig. 5A]), we disrupted these motifs in the context of the $-1135/-5$ reporter construct and tested the mutated promoter activity by using transient-transfection assays with

HUVECs and HEK-293 cells (Fig. 6A). In HUVECs, the E^{-784} mutated promoter exhibited a strong reduction (66%) in activity compared to that of the wild-type promoter. In contrast, the mutation of the E^{-101} element produced a significant 80% increase in luciferase activity. Opposite observations were made with HEK-293 cells, in which the basal activity of the




FIG. 6. *VE-cadherin* promoter activity in endothelial cells is dependent on a specialized E-box–GATA element. (A) HUVECs or HEK-293 cells were transfected with either the wild-type $-1135/-5$ promoter construct or the $-1135/-5$ promoter construct with the indicated mutation(s). Three independent clones were tested for each mutation. Data are the means \pm SD from three experiments performed in triplicate and are shown relative to the luciferase activity of cells transfected with the wild-type promoter construct, which was assigned a value of 1. (***, $P < 0.001$; *, $P < 0.05$.) (B) Silencing of TAL-1, E47, or LMO2 reduces the activity of the *VE-cadherin* promoter in the absence of functional E⁻¹⁰¹. HUVECs were transfected by the indicated siRNA and 24 h later with the *VE-cadherin* $-1135/-5$ promoter reporter in which E⁻¹⁰¹ was mutated. Relative luciferase activities are presented as increases (n -fold) over the activity of the E⁻¹⁰¹ mutated promoter treated with control GFP siRNA, which was assigned a value of 1. Each bar is the mean \pm SD from three independent experiments, each performed in triplicate. TAL-1 and E47 silencing was monitored by immunoblot analysis and LMO2 silencing by RT-qPCR (not shown). (**, $P < 0.01$; *, $P < 0.05$.) (C) TAL-1, E47, LMO2, and GATA-2 are recruited to the *VE-cadherin* promoter in HUVECs. ChIP assays were performed on cross-linked chromatin from HUVECs, as described in Materials and Methods (see the supplemental material for a detailed description). Aliquots of immunoprecipitated DNAs were analyzed in triplicate by RT-qPCR with primers targeting the G⁻⁷⁹⁸/E⁻⁷⁸⁴ region. The genomic region downstream of the *VE-cadherin* gene (+40932) was amplified as a negative control. Enrichment (n -fold) of target genomic regions immunoprecipitated by each specific antibody was normalized to the levels obtained with species-matched control IgGs, assigned a value of 1, and plotted as the increase over the level of enrichment at the negative control region. The error bars represent SD from at least two independent ChIP assays. (**, $P < 0.01$; *, $P < 0.05$.)

VE-cadherin reporter was abolished by the E⁻¹⁰¹ mutation but not affected by the E⁻⁷⁸⁴ mutation.

These experiments demonstrated that the E⁻⁷⁸⁴ element was required for endothelial-specific activity of the *VE-cadherin* promoter. In contrast, the E⁻¹⁰¹ element exerted negative effects on the promoter in endothelial cells, whereas it functioned as a positive element in nonendothelial cells.

Importantly, the mutation of GATA⁻⁷⁹⁸, located 8 bp upstream of E⁻⁷⁸⁴, also induced a strong 70% reduction in *VE-cadherin* promoter activity in HUVECs but not in HEK-293 cells (Fig. 6A). Disruption of both E⁻⁷⁸⁴ and G⁻⁷⁹⁸ provoked a similar 70% decrease in promoter activity in HUVECs, as did individual mutation of E⁻⁷⁸⁴ or G⁻⁷⁹⁸. Meaningfully, knock-down of TAL-1, E47, or LMO2 still induced a significant reduction in the activity of the mutated E⁻¹⁰¹ reporter construct, in which the G⁻⁷⁹⁸-E⁻⁷⁸⁴ motif was intact (Fig. 6B). Altogether, these assays identified a critical role for the G⁻⁷⁹⁸-E⁻⁷⁸⁴ motif for *VE-cadherin* promoter activity in endothelial cells.

TAL-1, E47, LMO2, and GATA-2 are recruited to the *VE-cadherin* promoter in HUVECs. Our above-described observations were consistent with the possibility that TAL-1, E47, LMO2, and GATA-2 work together in a complex, as has been shown for erythroid cells (1, 5, 21, 27, 44–46), to activate the *VE-cadherin* promoter through binding to the G⁻⁷⁹⁸-E⁻⁷⁸⁴ motif. To test this possibility, chromatin immunoprecipitation assays were performed with HUVECs, using anti-TAL-1, anti-LMO-2, anti-E47, and anti-GATA-2 antibodies as well as control immunoglobulins. The amounts of specific genomic fragments in immunoprecipitated samples were determined individually by real-time quantitative PCR. Primers were cho-

sen to amplify the *VE-cadherin* promoter region including the G⁻⁷⁹⁸-E⁻⁷⁸⁴ motif (Fig. 6C). The genomic region downstream of *VE-cadherin* (+40932 from the transcription start site) was used as a negative control in PCR analysis.

ChIP assays with anti-acetylated histone H3, which is a mark of active chromatin, were performed as a positive control for the quality of chromatin (not shown). As shown




FIG. 7. Knockdown of *VE-cadherin* (VE-CAD) impairs in vitro tubulogenesis. HUVECs were transfected twice with the indicated siRNA and analyzed 24 h after the second transfection for their ability to produce an in vitro tubular network in 3D collagen I gel. Shown are phase-contrast microscopic photographs, taken using a 10 \times objective, after 48 h of culture in collagen I gel. The residual protein expression was monitored by immunoblot analysis using 30 μ g whole-cell extracts. A representative experiment of three is shown.

in Fig. 6C, TAL-1, E47, LMO2, and GATA-2 were all found to bind the G^{-798} - E^{-784} region of the *VE-cadherin* promoter in HUVECs.

VE-cadherin silencing causes the same defects of in vitro tubulogenesis as TAL-1 silencing. Our above-described results demonstrated that the morphogenetic defects resulting from silencing of TAL-1, E47, or LMO2 correlated with down-regulation of VE-cadherin expression. Meaningfully, a decrease in VE-cadherin expression mediated by *VE-cadherin* siRNA (Fig. 7) provoked a behavior of HUVECs during in vitro tubulogenesis similar to that of TAL-1-silenced ECs (Fig. 1C). Indeed, unlike control ECs, *VE-cadherin*-silenced ECs did not establish cell-cell contacts and did not form tubular structures. This indicates that VE-cadherin down-expression induced by depletion of TAL-1 or its cofactor is a major event accounting for an EC-deficient phenotype during in vitro tubulogenesis.

DISCUSSION

In addition to its essential role in hematopoiesis, TAL-1 is crucial for vascular development and more particularly for embryonic angiogenesis (43). We previously reported that TAL-1 acts as a positive factor for postnatal angiogenesis (23). Here, we investigated how TAL-1 modulates this process, utilizing siRNA technology to block TAL-1 expression in human primary ECs. Our data demonstrate that TAL-1 silencing impairs in vitro tubulogenesis and strongly reduces VE-cadherin expression. Accordingly, several approaches demonstrated a direct role of TAL-1 together with E47, LMO2, and GATA-2 in up-regulation of *VE-cadherin* in ECs. Our findings identify *VE-cadherin* as a bona fide target of the TAL-1 complex in the endothelial lineage.

TAL-1 mediates endothelial morphogenesis through regulation of VE-cadherin expression. Capillary tube formation is a specialized endothelial cell function and is a prerequisite for the establishment of a continuous vessel lumen. ECs lacking TAL-1 are unable to initiate in vitro morphogenesis, defined here as the process whereby ECs assemble into cell cords in a 2D culture (Matrigel) or into tubes in a 3D matrix (collagen I). The defect was not due to perturbation in cell survival or growth in our experimental conditions, in agreement with our previous observations that overexpression of TAL-1 or a mutant that lacks the DNA-binding domain did not modify EC growth properties (23). However, this contradicts recent in vitro studies reporting a growth defect of *Tal-1*-deficient ECs (8, 9). This apparent discrepancy probably reflects the difference between transient silencing of TAL-1 and its total absence observed in ECs from the start.

TAL-1-silenced ECs do not develop normal cell-to-cell contacts, a prerequisite for initiating morphogenesis. Among the potential mediators, VE-cadherin stood out as an attractive candidate. VE-cadherin is an essential component in endothelial morphogenesis (3, 14), and the in vitro morphogenetic defects caused by TAL-1 silencing resemble that observed with antibodies blocking VE-cadherin adhesions (48). Here, we found that TAL-1 depletion leads to a vast decrease in VE-cadherin at the cell-cell junctions, which corresponds to diminished *VE-cadherin* transcription. VE-cadherin down-regulation appears as a major event accounting for the deficient phenotype of TAL-1-silenced ECs. Indeed, reduction in VE-cadherin

mediated by *VE-cadherin*-targeting siRNA causes the same morphogenetic defects during the process of in vitro tubulogenesis.

TAL-1 acts together with LMO2, E47, and GATA-2 in a multiprotein complex to activate the *VE-cadherin* promoter. In hematopoietic cells, TAL-1 transactivates transcription if all of its appropriate partners are recruited to the promoter. To activate hematopoietic-specific genes, TAL-1 requires the presence of E47, LMO2, Ldb1, and GATA-1 or GATA-2 (1, 5, 21, 27, 44–46). Given that all of these factors are present in ECs, we speculated that a similar multiprotein complex might positively regulate *VE-cadherin*.

Consistently, TAL-1, E47, and LMO-2 knockdowns in ECs cause similar strong reductions in endogenous *VE-cadherin* expression and reduce the activity of the *VE-cadherin* promoter in transient transfections in HUVECs. Meaningfully, ectopic coexpression of TAL-1 with E47 and LMO-2 in nonendothelial cells is able to up-regulate endogenous *VE-cadherin* transcription, whereas ectopic expression of each factor alone has no effect. From the data obtained with TAL-1 mutants, we conclude that, to exert this transcriptional function, TAL-1 is required to bind DNA and to interact with both E47 and LMO2.

Our experiments establish that TAL-1 acts jointly with E47, LMO2, and GATA-2 in a multiprotein complex to activate the *VE-cadherin* promoter. First, transient transfections demonstrate that *VE-cadherin* promoter activity in ECs is dependent on a specialized E-box (E^{-784}) in close association with a proximal GATA element, as has been described for the promoter of target genes of the TAL-1 complex in erythroid cells. Importantly, the sequence of E-box $^{-784}$ matches the preferred consensus E-box sequence (CAGATG) determined for the heterodimers TAL-1/E, where the half site “ATG” is bound by TAL-1 (16). Second, mutations that disrupt the E-box, the GATA element, or both provoke similar strong reductions in the activity of the promoter in ECs but not in nonendothelial cells. Third, exogenous expression of TAL-1, E47, GATA-2, or Ldb1 activates the *VE-cadherin* promoter in HUVECs; however, the maximal activation requires the concomitant expression of all components of the complex, including LMO2. Finally, ChIP experiments show that these different factors occupy this promoter region in HUVECs.

Complex regulation of *VE-cadherin* expression. In this study, we identified a second highly conserved E-box (E^{-101}) in the proximal promoter, which exerts a negative effect on the promoter in endothelial cells but is required for its basal activity in nonendothelial cells. Unlike the E^{-784} element, the palindromic sequence of E^{-101} (CAGCTG) should favor the binding of homodimers, such as E/E or other unknown factors, but not TAL-1 heterodimers. Accordingly, the activity of the promoter in which E^{-101} was disrupted was still affected by the depletion of TAL-1 or its partners in endothelial cells. The E^{-101} mutation rendered the promoter more active in ECs, suggesting the presence of one or several repressors that might interact directly with this element in the promoter. One candidate is SNAIL, a potent repressor that has been shown to inhibit *E-cadherin* expression through its binding to specific E-boxes in the promoter (2). Recently, SNAIL induction was correlated with *VE-cadherin* repression in specialized ECs during cardiac development (42), and importantly SNAIL was

shown to directly repress the *VE-cadherin* proximal promoter in porcine aortic ECs (42).

Given its essential function in the vascular system, *VE-cadherin* must be tightly controlled through a complex interplay between positive and negative regulators, similarly to that of *E-cadherin*. Endothelial cells derived from *Tal-1*^{-/-} embryonic bodies express *VE-cadherin* at their surface (28), indicating that the TAL-1 complex is not the sole transcriptional activator of the *VE-cadherin* promoter. Notably, ETS-1 protein activates the *VE-cadherin* proximal promoter through binding to two ETS-binding sites present in both mouse and human genes (13, 26, 34). Our studies suggest that dynamic fluctuations of TAL-1 and its partners on the *VE-cadherin* promoter likely contribute to the precise timing of *VE-cadherin* expression in ECs. Up-regulation of *VE-cadherin* coincided with the induction of both TAL-1 and LMO2 during in vitro angiogenesis (Fig. 4A). At the initiation of morphogenesis, increases in TAL-1 and LMO2 would trigger up-regulation of *VE-cadherin*, as well as other unidentified TAL-1 target genes. Although the elevation of *VE-cadherin* expression in angiogenesis has been documented previously (19, 30, 34), this is the first *VE-cadherin* expression study associating a morphogenetic event with a transcriptional mechanism.

The involvement of both TAL-1 and LMO2 in the up-regulation of *VE-cadherin* is strongly supported by the similar vascular defects in early development caused by their respective knockouts (3, 14, 43, 47). The deficiency of any of the three genes does not affect the assembly of ECs in the primitive vascular plexus but impairs their subsequent remodeling by angiogenesis, causing lethality at 9.5 days of gestation. Thus, it is possible that the phenotype alterations observed for *Lmo2*^{-/-} and *Tal-1*^{-/-} embryos might be the consequence of the absence of up-regulation of *VE-cadherin* during angiogenesis due to the lack of one of these two transcription factors.

In conclusion, our study demonstrates that *VE-cadherin* is an important component of the genetic program controlled by TAL-1 in the endothelial lineage. Establishing the compendium of TAL-1 transcriptional targets in ECs should help to determine whether TAL-1 is dedicated solely to the up-regulation of *VE-cadherin* expression or whether it also promotes the expression of other genes important for endothelial cell function.

ACKNOWLEDGMENTS

We are indebted to Valérie Pinet and Philippe Couttet for helpful discussions and to Robert Hipskind for critical reading of the manuscript. We acknowledge Olivier Bernard, Trang Hoang, and Catherine Porcher for providing us with cDNA reagents and Gerlinde Layh-Schmitt for the anti-LMO2 antibody. We are grateful to Ignacio A. Romero and Babette Wekler for the hCMC/D3 endothelial cell line. We thank Pierre Travo and Julien Cau (RIO Platform, Montpellier, France) for their constant help with imaging studies.

V.D. was a fellowship recipient of the Ligue Nationale Contre le Cancer (France) and is now funded by the Institut National du Cancer (INCa, France). E.C. was a recipient of the Association pour la Recherche sur le Cancer (ARC, France). R.E.-H. is supported by the Ligue Régionale contre le Cancer (Hérault, France) and D.M. by the Institut National de la Santé et de la Recherche Médicale (INSERM, France). This work was supported in part by grants from ARC and Cancéropôle Grand Sud-Ouest (France).

REFERENCES

- Anguita, E., J. Hughes, C. Heyworth, G. A. Blobel, W. G. Wood, and D. R. Higgs. 2004. Globin gene activation during haemopoiesis is driven by protein complexes nucleated by GATA-1 and GATA-2. *EMBO J.* **23**:2841–2852.
- Batlle, E., E. Sancho, C. Franci, D. Dominguez, M. Monfar, J. Baulida, and A. Garcia De Herreros. 2000. The transcription factor snail is a repressor of E-cadherin gene expression in epithelial tumour cells. *Nat. Cell Biol.* **2**:84–89.
- Carmeliet, P., M. G. Lampugnani, L. Moons, F. Breviaro, V. Compernelle, F. Bono, G. Balconi, R. Spagnuolo, B. Oostuyse, M. Dewerchin, A. Zanetti, A. Angellilo, V. Mattot, D. Nuyens, E. Lutgens, F. Clotman, M. C. de Ruiter, A. Gittenberger-de Groot, R. Poelmann, F. Lupu, J. M. Herbert, D. Collen, and E. Dejana. 1999. Targeted deficiency or cytosolic truncation of the *VE-cadherin* gene in mice impairs VEGF-mediated endothelial survival and angiogenesis. *Cell* **98**:147–157.
- Chetty, R., M. A. Dada, C. H. Boshoff, M. A. Comley, S. C. Biddolph, J. W. Schneider, D. Y. Mason, K. A. Pulford, and K. C. Gatter. 1997. TAL-1 protein expression in vascular lesions. *J. Pathol.* **181**:311–315.
- Cohen-Kaminsky, S., L. Maouche-Chretien, L. Vitelli, M. A. Vinit, I. Blanchard, M. Yamamoto, C. Peschle, and P. H. Romeo. 1998. Chromatin immunoselection defines a TAL-1 target gene. *EMBO J.* **17**:5151–5160.
- Davis, G. E., K. J. Bayless, and A. Mavila. 2002. Molecular basis of endothelial cell morphogenesis in three-dimensional extracellular matrices. *Anat. Rec.* **268**:252–275.
- Dejana, E. 2004. Endothelial cell-cell junctions: happy together. *Nat. Rev. Mol. Cell Biol.* **5**:261–270.
- D'Souza, S. L., A. G. Elefanty, and G. Keller. 2005. SCL/Tal-1 is essential for hematopoietic commitment of the hemangioblast but not for its development. *Blood* **105**:3862–3870.
- Ema, M., P. Faloony, W. J. Zhang, M. Hirashima, T. Reid, W. L. Stanford, S. Orkin, K. Choi, and J. Rossant. 2003. Combinatorial effects of Flk1 and Tal1 on vascular and hematopoietic development in the mouse. *Genes Dev.* **17**:380–393.
- Gering, M., A. R. Rodaway, B. Gottgens, R. K. Patient, and A. R. Green. 1998. The SCL gene specifies haemangioblast development from early mesoderm. *EMBO J.* **17**:4029–4045.
- Gering, M., Y. Yamada, T. H. Rabbitts, and R. K. Patient. 2003. Lmo2 and Scl/Tal1 convert non-axial mesoderm into haemangioblasts which differentiate into endothelial cells in the absence of Gata1. *Development* **130**:6187–6199.
- Goardon, N., J. A. Lambert, P. Rodriguez, P. Nissaire, S. Herblot, P. Thibault, D. Dumenil, J. Strouboulis, P. H. Romeo, and T. Hoang. 2006. ETO2 coordinates cellular proliferation and differentiation during erythropoiesis. *EMBO J.* **25**:357–366.
- Gory, S., J. Dalmon, M. H. Prandini, T. Kortulewski, Y. de Launoit, and P. Huber. 1998. Requirement of a GT box (Sp1 site) and two Ets binding sites for vascular endothelial cadherin gene transcription. *J. Biol. Chem.* **273**:6750–6755.
- Gory-Faure, S., M. H. Prandini, H. Pointu, V. Roullot, I. Pignot-Paintrand, M. Vernet, and P. Huber. 1999. Role of vascular endothelial-cadherin in vascular morphogenesis. *Development* **126**:2093–2102.
- Hall, M. A., D. J. Curtis, D. Metcalf, A. G. Elefanty, K. Sourris, L. Robb, J. R. Gothert, S. M. Jane, and C. G. Begley. 2003. The critical regulator of embryonic hematopoiesis, SCL, is vital in the adult for megakaryopoiesis, erythropoiesis, and lineage choice in CFU-S12. *Proc. Natl. Acad. Sci. USA* **100**:992–997.
- Hsu, H. L., L. Huang, J. T. Tsan, W. Funk, W. E. Wright, J. S. Hu, R. E. Kingston, and R. Baer. 1994. Preferred sequences for DNA recognition by the TAL1 helix-loop-helix proteins. *Mol. Cell. Biol.* **14**:1256–1265.
- Huang, S., and S. J. Brandt. 2000. mSin3A regulates murine erythroleukemia cell differentiation through association with the TAL1 (or SCL) transcription factor. *Mol. Cell. Biol.* **20**:2248–2259.
- Huang, S., Y. Qiu, R. W. Stein, and S. J. Brandt. 1999. p300 functions as a transcriptional coactivator for the TAL1/SCL oncoprotein. *Oncogene* **18**:4958–4967.
- Hubank, M., and D. G. Schatz. 1994. Identifying differences in mRNA expression by representational difference analysis of cDNA. *Nucleic Acids Res.* **22**:5640–5648.
- Kallianpur, A. R., J. E. Jordan, and S. J. Brandt. 1994. The SCL/TAL-1 gene is expressed in progenitors of both the hematopoietic and vascular systems during embryogenesis. *Blood* **83**:1200–1208.
- Lahlil, R., E. Lecuyer, S. Herblot, and T. Hoang. 2004. SCL assembles a multifactorial complex that determines glycophorin A expression. *Mol. Cell. Biol.* **24**:1439–1452.
- Lampugnani, M. G., M. Corada, L. Caveda, F. Breviaro, O. Ayalon, B. Geiger, and E. Dejana. 1995. The molecular organization of endothelial cell to cell junctions: differential association of plakoglobin, beta-catenin, and alpha-catenin with vascular endothelial cadherin (VE-cadherin). *J. Cell Biol.* **129**:203–217.
- Lazrak, M., V. Deleuze, D. Noel, D. Haouzi, E. Chalhoub, C. Dohet, I.

- Robbins, and D. Mathieu. 2004. The bHLH TAL-1/SCL regulates endothelial cell migration and morphogenesis. *J. Cell Sci.* **117**:1161–1171.
24. Le Clech, M., E. Chalhoub, C. Dohet, V. Roure, S. Fichelson, F. Moreau-Gachelin, and D. Mathieu. 2006. PU.1/Spi-1 binds to the human TAL-1 silencer to mediate its activity. *J. Mol. Biol.* **355**:9–19.
 25. Lecuyer, E., and T. Hoang. 2004. SCL: from the origin of hematopoiesis to stem cells and leukemia. *Exp. Hematol.* **32**:11–24.
 26. Lelievre, E., V. Mattot, P. Huber, B. Vandenbunder, and F. Soncin. 2000. ETS1 lowers capillary endothelial cell density at confluence and induces the expression of VE-cadherin. *Oncogene* **19**:2438–2446.
 27. McCormack, M. P., M. A. Hall, S. M. Schoenwaelder, Q. Zhao, S. Ellis, J. A. Prentice, A. J. Clarke, N. J. Slater, J. M. Salmon, S. P. Jackson, S. M. Jane, and D. J. Curtis. 2006. A critical role for the transcription factor Scl in platelet production during stress thrombopoiesis. *Blood* **108**:2248–2256.
 28. Mikkola, H. K., J. Klintman, H. Yang, H. Hock, T. M. Schlaeger, Y. Fujiwara, and S. H. Orkin. 2003. Haematopoietic stem cells retain long-term repopulating activity and multipotency in the absence of stem-cell leukaemia SCL/tal-1 gene. *Nature* **421**:547–551.
 29. Navarro, P., L. Ruco, and E. Dejana. 1998. Differential localization of VE- and N-cadherins in human endothelial cells: VE-cadherin competes with N-cadherin for junctional localization. *J. Cell Biol.* **140**:1475–1484.
 30. Parker, B. S., P. Argani, B. P. Cook, H. Liangfeng, S. D. Chartrand, M. Zhang, S. Saha, A. Bardelli, Y. Jiang, T. B. St. Martin, M. Nacht, B. A. Teicher, K. W. Klinger, S. Sukumar, and S. L. Madden. 2004. Alterations in vascular gene expression in invasive breast carcinoma. *Cancer Res.* **64**:7857–7866.
 31. Patterson, L. J., M. Gering, and R. Patient. 2005. Scl is required for dorsal aorta as well as blood formation in zebrafish embryos. *Blood* **105**:3502–3511.
 32. Porcher, C., E. C. Liao, Y. Fujiwara, L. I. Zon, and S. H. Orkin. 1999. Specification of hematopoietic and vascular development by the bHLH transcription factor SCL without direct DNA binding. *Development* **126**:4603–4615.
 33. Porcher, C., W. Swat, K. Rockwell, Y. Fujiwara, F. W. Alt, and S. H. Orkin. 1996. The T cell leukemia oncoprotein SCL/tal-1 is essential for development of all hematopoietic lineages. *Cell* **86**:47–57.
 34. Prandini, M. H., I. Dreher, S. Bouillot, S. Benkerri, T. Moll, and P. Huber. 2005. The human VE-cadherin promoter is subjected to organ-specific regulation and is activated in tumour angiogenesis. *Oncogene* **24**:2992–3001.
 35. Pulford, K., N. Lecointe, K. Leroy-Viard, M. Jones, D. Mathieu-Mahul, and D. Y. Mason. 1995. Expression of TAL-1 proteins in human tissues. *Blood* **85**:675–684.
 36. Ravet, E., D. Reynaud, M. Titeux, B. Izac, S. Fichelson, P. H. Romeo, A. Dubart-Kupperschmitt, and F. Pflumio. 2004. Characterization of DNA-binding-dependent and -independent functions of SCL/TAL1 during human erythropoiesis. *Blood* **103**:3326–3335.
 37. Robb, L., N. J. Elwood, A. G. Elefanty, F. Kontgen, R. Li, L. D. Barnett, and C. G. Begley. 1996. The scl gene product is required for the generation of all hematopoietic lineages in the adult mouse. *EMBO J.* **15**:4123–4129.
 38. Robb, L., I. Lyons, R. Li, L. Hartley, F. Kontgen, R. P. Harvey, D. Metcalf, and C. G. Begley. 1995. Absence of yolk sac hematopoiesis from mice with a targeted disruption of the scl gene. *Proc. Natl. Acad. Sci. USA* **92**:7075–7079.
 39. Schlaeger, T. M., A. Schuh, S. Flitter, A. Fisher, H. Mikkola, S. H. Orkin, P. Vyas, and C. Porcher. 2004. Decoding hematopoietic specificity in the helix-loop-helix domain of the transcription factor SCL/Tal-1. *Mol. Cell. Biol.* **24**:7491–7502.
 40. Schuh, A. H., A. J. Tipping, A. J. Clark, I. Hamlett, B. Guyot, F. J. Iborra, P. Rodriguez, J. Strouboulis, T. Enver, P. Vyas, and C. Porcher. 2005. ETO-2 associates with SCL in erythroid cells and megakaryocytes and provides repressor functions in erythropoiesis. *Mol. Cell. Biol.* **25**:10235–10250.
 41. Shivasani, R. A., E. L. Mayer, and S. H. Orkin. 1995. Absence of blood formation in mice lacking the T-cell leukaemia oncoprotein tal-1/SCL. *Nature* **373**:432–434.
 42. Timmerman, L. A., J. Grego-Bessa, A. Raya, E. Bertran, J. M. Perez-Pomares, J. Diez, S. Aranda, S. Palomo, F. McCormick, J. C. Izpisua-Belmonte, and J. L. de la Pompa. 2004. Notch promotes epithelial-mesenchymal transition during cardiac development and oncogenic transformation. *Genes Dev.* **18**:99–115.
 43. Visvader, J. E., Y. Fujiwara, and S. H. Orkin. 1998. Unsuspected role for the T-cell leukemia protein SCL/tal-1 in vascular development. *Genes Dev.* **12**:473–479.
 44. Vitelli, L., G. Condorelli, V. Lulli, T. Hoang, L. Luchetti, C. M. Croce, and C. Peschle. 2000. A pentamer transcriptional complex including tal-1 and retinoblastoma protein downmodulates c-kit expression in normal erythroblasts. *Mol. Cell. Biol.* **20**:5330–5342.
 45. Wadman, I. A., H. Osada, G. G. Grutz, A. D. Agulnick, H. Westphal, A. Forster, and T. H. Rabbitts. 1997. The LIM-only protein Lmo2 is a bridging molecule assembling an erythroid, DNA-binding complex which includes the TAL1, E47, GATA-1 and Ldb1/NLI proteins. *EMBO J.* **16**:3145–3157.
 46. Xu, Z., S. Huang, L. S. Chang, A. D. Agulnick, and S. J. Brandt. 2003. Identification of a TAL1 target gene reveals a positive role for the LIM domain-binding protein Ldb1 in erythroid gene expression and differentiation. *Mol. Cell. Biol.* **23**:7585–7599.
 47. Yamada, Y., R. Pannell, A. Forster, and T. H. Rabbitts. 2000. The oncogenic LIM-only transcription factor Lmo2 regulates angiogenesis but not vasculogenesis in mice. *Proc. Natl. Acad. Sci. USA* **97**:320–324.
 48. Yang, S., J. Graham, J. W. Kahn, E. A. Schwartz, and M. E. Gerritsen. 1999. Functional roles for PECAM-1 (CD31) and VE-cadherin (CD144) in tube assembly and lumen formation in three-dimensional collagen gels. *Am. J. Pathol.* **155**:887–895.